Cancer Profiling Market Overview, Analysis And Demand By 2034
Ideal for market intelligence professionals and business strategists, this research uncovers where growth is headed in the cancer profiling industry.
How Fast Is The Cancer Profiling Market Growing Towards 2025?
The cancer profiling market size has grown rapidly in recent years. It will grow from $13.48 billion in 2024 to $15 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing cancer incidence rates, rise in precision medicine approaches, clinical adoption of biomarkers, drug development and targeted therapies, awareness, and patient advocacy.
The cancer profiling market size is expected to see rapid growth in the next few years. It will grow to $22.97 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to integration of artificial intelligence, global collaborations in research, expansion of liquid biopsy applications, regulatory support for precision medicine, increasing emphasis on early detection. Major trends in the forecast period include liquid biopsy dominance, comprehensive genomic profiling, rise of immunoprofiling, collaborative data sharing network, single-cell sequencing.
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp
Cancer Profiling Market Drivers And Opportunities
The increasing incidence of cancer is expected to propel the growth of the cancer profiling market going forward. Incidence of cancer refers to the number of new cancer cases in a specific population for a given period. The increased incidence of cancer caused due to urbanization, a growing aging population, changing lifestyles, and environmental and genetic factors. Cancer profiling aids in the identification of specific molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA, which is helpful in the cancer treatment cycle. For instance, in 2022, according to the American Cancer Society, a US-based voluntary organization, the number of new cancer cases and fatalities expected was estimated to be 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Therefore, the increasing incidence of cancer is driving the growth of the cancer profiling market.
How Is The Cancer Profiling Market Segmented?
The cancer profilingmarket covered in this report is segmented –
1) By Technology: Immunoassays; PCR (Polymerized Chain Reaction); NGS (Next-Generation Sequencing); Microarrays; In-Situ Hybridization
2) By Biomarker Type: Genomic Biomarkers; Protein Biomarkers
3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma Cancer; Other Cancers
4) By Application: Research Applications; Clinical Applications; Screening; Diagnostics; Prognostics; Other Applications
Subsegments:
1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Luminex xMAP Technology; Radioimmunoassays
2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR); Digital PCR (dPCR); Reverse Transcription PCR (RT-PCR)
3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS); Whole Exome Sequencing (WES); Targeted Sequencing; RNA Sequencing (RNA-Seq)
4) By Microarrays: DNA Microarrays; RNA Microarrays; SNP Arrays
5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH); Chromogenic In-Situ Hybridization (CISH)
What Are The Future Trends Of The Cancer Profiling Market?
Major companies operating in the cancer profiling market are focused on developing innovation, such as broad coverage. The test evaluates 517 cancer-relevant genes across nearly 30 solid tumor types. Broad coverage refers to the comprehensive analysis of a wide range of genetic mutations, biomarkers, or molecular targets. For instance, in March 2022, Illumina, Inc., a US-based biotechnology company, launched the TruSight Oncology Comprehensive (TSO) test, marking a significant advancement in cancer diagnostics. A new in vitro diagnostic test in Europe profiles cancer mutations to guide patients toward targeted therapies. It covers 517 genes across nearly 30 solid tumor types, analyzing both DNA and RNA. With a four- to five-day turnaround, it delivers faster results and is CE-marked for European quality standards, reducing the need for multiple gene assays on different tissue samples.
Major Companies Operating In The Cancer Profiling Market Are:
Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation
View the full cancer profiling market report here:
https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report
Regional Analysis: Opportunities And Challenges In The Cancer Profiling Market
North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment